Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Oncology Research and Treatment

Vol. 39, No. 1-2, 2016

Issue release date: February 2016

Add all to MyReading List
FREE ONLINE ACCESS
 
1

Editorial Board / Contents / Imprint / Guidelines for Authors

Oncol Res Treat 2016;39:1-6 (DOI:10.1159/000444105)
Free Access
Editorial
8

Pathogenesis, Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Exciting Times

Hallek M.
Oncol Res Treat 2016;39:8 (DOI:10.1159/000443821)
Free Access
Review Article
9

Concepts of Chronic Lymphocytic Leukemia Pathogenesis: DNA Damage Response and Tumor Microenvironment

Frenzel L.P. · Reinhardt H.C. · Pallasch C.P.
Oncol Res Treat 2016;39:9-16 (DOI:10.1159/000443820)
Free Access
18

Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia

Langerbeins P. · Groß-Ophoff-Müller C. · Herling C.D.
Oncol Res Treat 2016;39:18-24 (DOI:10.1159/000443013)
Free Access
25

State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia

Cramer P. · Hallek M. · Eichhorst B.
Oncol Res Treat 2016;39:25-32 (DOI:10.1159/000443903)
Editor's Choice - Free Access
34

Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia

Tausch E. · Mertens D. · Stilgenbauer S.
Oncol Res Treat 2016;39:34-40 (DOI:10.1159/000443906)
Free Access
Original Article
41

Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014

Weide R. · Feiten S. · Friesenhahn V. · Heymanns J. · Kleboth K. · Thomalla J. · van Roye C. · Köppler H.
Oncol Res Treat 2016;39:41-44 (DOI:10.1159/000442769)
Free Access
45

Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western China

Liang R. · Wang Z. · Bai Q.-X. · Gao G.-X. · Yang L. · Zhang T. · Gu H.-T. · Dong B.-X. · Shu M.-M. · Hao C.-X. · Zhang N. · Chen X.-Q.
Oncol Res Treat 2016;39:45-52 (DOI:10.1159/000442763)
Free Access
54

Reactive Oxygen Species Mediate TNF-⍺ Cytotoxic Effects in the Multidrug-Resistant Breast Cancer Cell Line MCF-7/MX

Ghandadi M. · Behravan J. · Abnous K. · Mosaffa F.
Oncol Res Treat 2016;39:54-59 (DOI:10.1159/000442144)
Free Access
61

Tumor Heterogeneity Assessed by 18F-FDG PET/CT Is Not Significantly Associated with Nodal Metastasis in Breast Cancer Patients

Shin S. · Pak K. · Park D.Y. · Kim S.J.
Oncol Res Treat 2016;39:61-66 (DOI:10.1159/000442760)
Free Access
 
67

Ongoing Clinical Trials

Oncol Res Treat 2016;39:67-68 (DOI:10.1159/000444031)
Free Access
Ongoing Clinical Trials
69

A Study to Compare the Efficacy and Safety of Obinutuzumab + Venetoclax versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL14)

Commentary Prof. Dr. med. Michael Hallek, Dr. med. Kirsten Fischer

Oncol Res Treat 2016;39:69-71 (DOI:10.1159/000443908)
Free Access
 
73

Reports of Oncological Societies

Oncol Res Treat 2016;39:73-77 (DOI:10.1159/000444107)
Free Access
78

PharmaForum

Oncol Res Treat 2016;39:78-79 (DOI:10.1159/000444225)
Free Access
80

PharmaForum

Oncol Res Treat 2016;39:80-81 (DOI:10.1159/000444226)
Free Access
83

PharmaNews

Oncol Res Treat 2016;39:83-87 (DOI:10.1159/000444227)
Free Access
90

Meetings and Conferences

Oncol Res Treat 2016;39:90-92 (DOI:10.1159/000444030)
Free Access
Beilage
I

Optimale Mobilisierungsstrategien für den individuellen Patienten

Oncol Res Treat 2016;39:I-IV (DOI:10.1159/000444403)
Free Access
V

Abirateronacetat: 43 Monate Überleben bei frühem Beginn

Oncol Res Treat 2016;39:V-VI (DOI:10.1159/000444402)
Free Access